Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Intrexon, Ziopharm license MD Anderson, U. Minnesota technologies for CART immunotherapies

Executive Summary

Intrexon Corp. and Ziopharm Oncology Inc. licensed exclusive worldwide rights to the University of TexasMD Anderson Cancer Center’s technologies relating to chimeric antigen receptor T (CART) cells, which they will use with their own DNA platforms to develop and commercialize synthetic cellular immunotherapies for cancer.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Synthesis Technologies, Production Processes
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register